U.S. CRISPR & Cas Genes Market Size Worth USD 8.29 Billion by 2034 | CAGR: 18.4%

The U.S. crispr & cas genes market size is expected to reach USD 8.29 billion by 2034, according to a new study by Polaris Market Research. The report “U.S. CRISPR & Cas Genes Market Size, Share, Trends, Industry Analysis Report By Product (Kits & Enzymes, Libraries), By Service, By Application, By End Use – Market Forecast, 2025–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

CRISPR-Cas genes refer to a natural bacterial defense system used for gene editing. The CRISPR sequences guide the Cas enzyme to specific DNA locations to make precise cuts.

The U.S. has a well-established patent system that supports innovation and protects proprietary CRISPR technologies. Institutes such as the Broad Institute and the University of California have secured foundational CRISPR-Cas9 patents, creating a structured framework for licensing and commercialization. This robust IP environment encourages research institutions and biotech startups to invest confidently in CRISPR development. Furthermore, exclusive licensing deals and cross-licensing agreements are enabling new partnerships and accelerating product development. A strong legal infrastructure for protecting gene-editing innovations gives U.S. companies a competitive edge in both domestic and international markets.

Bottom of Form

Have Questions? Request a sample or make an Inquiry before buying this report by clicking the link below: https://www.polarismarketresearch.com/industry-analysis/us-crispr-and-cas-genes-market/request-for-sample

Effective delivery of CRISPR components into human cells is crucial for successful gene editing, and U.S.-based researchers are leading in developing advanced delivery systems such as lipid nanoparticles, viral vectors, and electroporation methods. These innovations are improving the precision, efficiency, and safety of CRISPR-based interventions. Additionally, advancements in base editing and prime editing are opening new possibilities for correcting genetic mutations without double-stranded DNA breaks. This continuous evolution in gene-editing platforms improves the versatility and therapeutic potential of CRISPR in the U.S. market.

U.S. CRISPR & Cas Genes Market Report Highlights

• The kits & enzymes segment is projected to register a CAGR of 19.1% over the forecast period, owing to their essential role in facilitating gene-editing processes.
• The kits and enzymes segment is anticipated to register a CAGR of 19.3% during the forecast period, driven by the extensive adoption of gene-editing tools across academic and commercial research settings.
• The contract research organizations (CROs) segment held a significant revenue share of 15.59% in 2024, as they continue to provide specialized CRISPR-related research services to pharmaceutical and biotechnology companies.
• A few key players in the U.S. CRISPR & Cas genes market are Addgene, AstraZeneca, Caribou Biosciences, Inc., Cellectis, CRISPR Therapeutics, Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, and Wellcome Trust Sanger Institute.

Polaris Market Research has segmented the U.S. CRISPR & Cas genes market report based on product, service, application, end use, and region:

By Product (Revenue - USD Billion, 2020–2034)

• Kits & Enzymes
  • Vector-based Cas
  • DNA-free Cas
• Libraries
• Design Tool
• Antibodies
• Other Products

By Service (Revenue - USD Billion, 2020–2034)

• Cell Line Engineering
• gRNA Design
• Microbial Gene Editing
• DNA Synthesis

By Application (Revenue - USD Billion, 2020–2034)

• Biomedical
• Agricultural

By End Use (Revenue - USD Billion, 2020–2034)

• Biotechnology & Pharmaceutical Companies
• Academics & Government Research Institutes
• Contract Research Organizations (CROs)